Mara Goldstein
Stock Analyst at Mizuho
(2.49)
# 2,148
Out of 4,876 analysts
77
Total ratings
37.93%
Success rate
4.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $5.67 | +429.10% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $1.69 | +491.72% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $4.15 | +92.77% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $7.95 | +428.30% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $8.14 | +514.25% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $9.03 | +398.61% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $68.37 | +12.62% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.31 | +434.35% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.04 | +669.23% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.26 | +4,487.16% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $25.76 | +249.38% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $3.89 | -10.03% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.13 | +16,801.41% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $3.53 | +466.57% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $79.10 | +64.35% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $2.25 | -11.11% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $2.31 | +419.48% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.25 | +3,573.47% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $33.16 | -39.69% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.44 | +645.34% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.28 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $3.69 | +279.40% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $5.67
Upside: +429.10%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $1.69
Upside: +491.72%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.15
Upside: +92.77%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $7.95
Upside: +428.30%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $8.14
Upside: +514.25%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $9.03
Upside: +398.61%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $68.37
Upside: +12.62%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.31
Upside: +434.35%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.04
Upside: +669.23%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.26
Upside: +4,487.16%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $25.76
Upside: +249.38%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $3.89
Upside: -10.03%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.13
Upside: +16,801.41%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $3.53
Upside: +466.57%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $79.10
Upside: +64.35%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $2.25
Upside: -11.11%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $2.31
Upside: +419.48%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.25
Upside: +3,573.47%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $33.16
Upside: -39.69%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.44
Upside: +645.34%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $20.28
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $3.69
Upside: +279.40%